Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Imaging and genetic testing review timelines change

As of March 24, 2023, Carelon Medical Benefits Management (formerly AIM Specialty Health) will review prospective and retroactive authorizations up to 60 calendar days from the date of service. Previously, the review was up to two days from the date of service. This change applies to imaging and genetic testing for all lines of business. Our Authorization Grid reflects this change.